< Three-Sentence Summary >

1. Resveratrol supplementation shifted SAA, triglycerides, and adiponectin in obese cats – the first direct feline evidence that RSV engages the inflammation-metabolism axis.

2. The core mechanisms – SIRT1 activation, NF-κB suppression, and Nrf2-driven antioxidant defense – provide a credible theoretical basis for its role in slowing renal aging and fibrosis.

3. This research was led directly by Greycoat Research CEO Claire J.E.Yun, and RSV is included as a core ingredient across the Greycoat product line.

< Introduction >

You may have heard of the French Paradox, the observation popularized in the early 1990s that people in France consumed relatively high amounts of saturated fats yet have lower rates of cardiovascular disease than expected. One proposed explanation was red wine. A single glass a day, the story went, might be doing something protective.

That story took on a life of its own. Red wine sales in the US reportedly jumped after a 1991 CBS segment on the subject. And when researchers began asking what in red wine might be responsible, one compound kept coming up: resveratrol (RSV), a polyphenol found naturally in grape skins, blueberries, and peanuts.

Through the 2000s, RSV was studied intensively as a potential longevity molecule, largely because of research linking it to SIRT1 activation. Harvard’s David Sinclair became closely associated with this field. The hype was considerable. Later, questions emerged around parts of the early research landscape, and the field became more cautious.

So where does that leave RSV today?

Probably somewhere between “overhyped” and “still genuinely interesting.” The early excitement has cooled, but the research has continued in a more careful way.

That brings us to a 2025 study that looked at RSV not in mice or humans, but directly in cats. And not just any study: this one was led by Claire J.E. Yun, CEO of Greycoat Research, as first author, with Prof. Arai Toshiro and Dr. Kobayashi Motoo as senior authors.

One important point should be made upfront: this is a study in obese cats, not cats with chronic kidney disease (CKD). So why discuss it in a kidney health context?

Because obesity, inflammation, and kidney health are more connected than they may first appear. Excess body fat can contribute to chronic low-grade inflammation, and chronic inflammation is one of the internal conditions that may place long-term stress on the body. RSV appears to act on this inflammation-metabolism axis. That connection is the main reason this study matters.

< Background >

Before going into the mechanisms, it may help to think of RSV as a compound being studied for how it interacts with the body’s internal “maintenance systems”.

These systems do not work like a drug that targets one disease directly. Instead, they are more like background controls: how cells handle energy, how strongly inflammatory signals are turned on, and how the body responds to oxidative stress. Three names come up often in RSV research: SIRT1, NF-κB, and Nrf2.

1. SIRT1 – The Cellular Maintenance Regulator

SIRT1 is an NAD+-dependent deacetylase enzyme often discussed in connection with aging, energy metabolism, and cellular repair. In simple terms, it helps cells manage energy more efficiently and may help keep excessive inflammatory signaling under control.

RSV is one of the best-known compounds studied for for SIRT1 activation. Through this pathway, RSV may influence NF-κB, one of the body’s major inflammatory signaling systems. This may lead to reduced production of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and may help regulate systemic inflammation.

2. NF-κB – The Inflammation Switch

NF-κB is a transcription factor, meaning it helps control how certain genes are turned on or off. It plays a major role in inflammation.

In chronic disease, including CKD, NF-κB can remain overactivated for long periods. RSV has been studied for its ability to regulate this pathway, partly through SIRT1. Put simply, this means RSV may help calm excessive inflammatory signaling rather than simply blocking inflammation in a one-dimensional way.

3. Nrf2 – The Antioxidant Defense Switch

Nrf2 is another transcription factor, but its role is different. It helps the body respond to oxidative stress

Oxidative stress can be thought of as “cellular rust”. When Nrf2 is activated, the body increases the expression of antioxidant-related enzymes, including SOD and HO-1. RSV has been reported to activate Nrf2-related pathways, which provides another possible explanation for why it continues to be studied in aging and kidney-related research.

< Main Study: RSV in Obese Cats >

Yun JE et al. “Effect of resveratrol supplementation on lipid metabolism in healthy and obese cats” Front Vet Sci. 2025 Apr 16;12:1565367.

Study Design

Cats were recruited from two private shelters in South Korea and divided into healthy, obese, and obesity-disease groups. RSV was administered in capsule form for four weeks at two dose levels:

• Low dose: 1 mg/kg/day
• High dose: 5 mg/kg/day

Blood parameters measured before and after supplementation included plasma triglycerides (TG), free fatty acids (FFA), cholesterol, insulin, albumin (ALB), blood urea nitrogen (BUN), serum amyloid A (SAA), and adiponectin.

Key Results

In overweight and obese cats, RSV supplementation was associated with:

• TG ↓ & FFA ↓ — changes related to lipid metabolism
• SAA ↓ — reduction in a systemic inflammation marker
• LDH activity ↓ — a finding that may suggest changes in hepatic function
• Adiponectin ↑ — increase in anti-inflammatory, insulin-sensitizing hormone

Parameters showing no significant change:

• Bodyweight, BCS, BUN, insulin — no significant change within the 4-week study period

In healthy cats whose parameters were already within normal range, RSV supplementation produced no significant changes. This is consistent with the idea that RSV may show more measurable effects when metabolic or inflammatory dysregulation is already present.

Why This Matters

SAA is an inflammatory marker our research team has positioned as an important part of feline CKD classification. In this study, the finding that RSV supplementation significantly reduced SAA in obese cats provides direct feline evidence that RSV may interact with the inflammation-metabolism axis.

This does not mean RSV has been shown to slow CKD progression in cats. It has not.

What it does suggest is more specific: in obese cats, RSV may influence inflammatory and metabolic markers that are relevant to long-term internal health. Because obesity, low-grade inflammation, and kidney-related stress can be biologically connected, this finding may be useful for future research on early health management and internal environment support.

< Supporting Evidence: Mechanisms Related to Kidney Health >

1. SIRT1-Nrf2 Activation and Aging Kidney Injury

Kishi et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018;10(2):276-285.

In this mouse study, researchers administered RSV to 18-month-old mice for six months. They reported changes in aging-related renal injury markers, including glomerulosclerosis and tubulointerstitial fibrosis.

The study also found increased expression of SIRT1/AMPK and Nrf2-HO-1 pathways in RSV-treated mice. When these pathways were knocked down, the protective effect was reduced. This supports the idea that RSV’s effects in this model were closely connected to SIRT1 and Nrf2 signaling.

This is important mechanistic evidence, but it is still animal-model evidence. It should not be read as direct proof of the same effect in cats with CKD.

2. RSV in Human CKD – Clinical Evidence

Saldanha JF et al. Effects of Resveratrol Supplementation in Nrf2 and NF-κB Expressions in Nondialyzed Chronic Kidney Disease Patients. J Ren Nutr. 2016;26(6):401-406.

In a double-blind, randomized, crossover clinical trial in non-dialyzed CKD patients, researchers reported that RSV supplementation reduced NF-κB expression and increased Nrf2 expression.

This is one of the few human randomized clinical trials supporting simultaneous modulation of inflammatory and antioxidant pathways by RSV in a CKD population.

Again, this is not feline CKD evidence. But it does support the biological plausibility of the pathways being discussed.

3. Gut-Kidney Axis and RSV

Tain YL, Chang CI, Hou CY et al. Dietary resveratrol butyrate monoester supplement improves hypertension and kidney dysfunction in a young rat chronic kidney disease model. Nutrients. 2023;15(3):635.

In an adenine-induced CKD rat model, researchers reported that an RSV butyrate ester supplement was associated with changes in blood pressure, kidney injury markers, serum creatinine, and gut microbiota composition.

This suggests that RSV may also interact with the gut-kidney axis, the biological connection between intestinal health, microbial metabolites, inflammation, and kidney-related physiology.

For cats, this remains an area for future study.

< Limitations >

• No direct CKD data in cats exists for RSV. The renal protection evidence discussed here comes from rodent models or human studies, not feline CKD cohorts.
• The main feline study lasted only four weeks, which is too short to draw conclusions about body weight, BCS, or insulin response, or long-term kidney-related outcomes.
• It is not yet clear whether the SAA reduction reflects RSV’s direct anti-inflammatory action, a secondary effect related to hepatic function, or a combination of multiple mechanisms.
• Feline pharmacokinetics (PK) data for RSV remains limited. Dose selection in the main study was extrapolated from rodent data rather than built from established feline PK studies.
• There is also no comparative feline data between standard RSV formulations and enhanced-bioavailability forms such as phytosome or liposomal RSV.

< Personal Thoughts >

Resveratrol has been oversold in the past. The gap between elegant mechanisms and real-world clinical effect size has been a recurring issue in RSV research, both in humans and animals. Bioavailability also remains a central challenge.

In cats specifically, the absence of direct CKD data is a real limitation and should be stated clearly. The main feline study shows that RSV can shift SAA and lipid-related markers in obese cats. It does not show that RSV slows CKD progression.

That said, the theoretical framework is still meaningful. The obesity–inflammation–kidney health connection is biologically plausible, SIRT1 and Nrf2 are credible mechanistic targets, and direct feline data are now available for obese cats.

For cats with obesity or metabolic dysregulation, RSV may be worth considering as part of broader internal environment support. It should not be framed as a CKD treatment, but as a compound that may support daily health management through pathways related to inflammation and metabolism.

When feline CKD cohort data eventually emerge, the current feline RSV study may serve as an important foundation. It is also worth noting that this research was conducted directly by Claire J.E. Yun, CEO of Greycoat Research. On that basis, RSV is included across the Greycoat product line as one part of a broader, research-informed approach to companion animal health.

The findings discussed in this article reflect associations, biomarkers, and theoretical mechanisms rather than confirmed clinical efficacy. Please consult a veterinarian before initiating any supplementation protocol.

< References >

1. Yun JE, Kang SR, Kim JY, Kim HJ, Kobayashi M, Arai T. Effect of resveratrol supplementation on lipid metabolism in healthy and obese cats. Front Vet Sci. 2025;12:1565367.

2. Kishi S et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018;10(2):276-285.

3. Saldanha JF et al. Effects of Resveratrol Supplementation in Nrf2 and NF-κB Expressions in Nondialyzed Chronic Kidney Disease Patients. J Ren Nutr. 2016;26(6):401-406.

4. Tain YL, Chang CI, Hou CY et al. Dietary resveratrol butyrate monoester supplement improves hypertension and kidney dysfunction in a young rat chronic kidney disease model. Nutrients. 2023;15(3):635.

5. Hasan M et al. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021;26(1):229.

< About the Author >

Hocheol Shin, Ph.D.

B.S./M.S./Ph.D. in Biological Sciences, KAIST (Korea Advanced Institute of Science and Technology)

Research background in cancer immunology, tumor microenvironment, and translational oncology. Currently engaged in companion animal health and longevity research.